Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.69), $0.14 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $1.17 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.